Overview and Regulatory Issues Regarding Anesthetic Agents for Pediatric Patients Anesthetics and Life Support Drugs Advisory Committee Meeting March 29,

Slides:



Advertisements
Similar presentations
Safety and Extrapolation Steven Hirschfeld, MD PhD Office of Cellular, Tissue and Gene Therapy Center for Biologics Evaluation and Research FDA.
Advertisements

Clinical Trials — A Closer Look. The Food and Drug Administration (FDA) is the main consumer watchdog for numerous products: Drugs and biologics (prescription.
JMV 1843 pharmacological profile
Introduction to Regulation
FDA Perspective Sally Loewke, M.D. Acting Division Director
CHAPTER 3 Life Span Considerations
The ICH E5 Question and Answer Document Status and Content Robert T. O’Neill, Ph.D. Director, Office of Biostatistics, CDER, FDA Presented at the 4th Kitasato-Harvard.
Pharmaceutical Development and Review Process Rev. 10/21/2014 APGO Interaction with Industry: A Medical Student Guide.
Procedural Sedation Pharmacology Deb Updegraff R.N., P.N.P, C.N.S. Clinical Nurse Specialist LPCH Pediatric Intensive Care Unit.
Guidance for Industry Establishing Pregnancy Registries Pregnancy Registry Working Group Pregnancy Labeling Taskforce March, 2000 Evelyn M. Rodriguez M.D.,
Neonatal/Juvenile Animal Safety Studies Kenneth L. Hastings, Dr.P.H., D.A.B.T. Office of New Drugs, CDER.
Effectiveness Evaluation for Therapeutic Drugs for Non-Food Animals
Postmarketing Risk Assessment of Drug Products Division of Drug Risk Evaluation Office of Drug Safety Center for Drug Evaluation and Research.
Clinical Trials of Traditional Herbal Medicines In India Y.K.Gupta Professor & Head, Department of Pharmacology, All India Institute of Medical Sciences,
The Risks of Cough/Cold Preparations to Young Children Michael Shannon, MD, MPH Children’s Hospital Boston Harvard Medical School.
HIV Drug Development in Neonates - What Now? Linda L. Lewis, M.D. Medical Officer Division of Antiviral Drug Products FDA.
CNS depressants CNS depressants
Yesterday, today, and tomorrow
Center for Drug Evaluation and Research August 2005 Electroretinography: The FDA’s Viewpoint Wiley A. Chambers, MD Deputy Director Division of Anti-Infective.
Adverse Event Tracking as mandated by the Best Pharmaceuticals for Children Act Dr. Solomon Iyasu Medical Team Leader Division of Pediatric Drug Development.
REGULATORY CHALLENGES FOR NANOMATERIALS IN PUBLIC HEALTH Driving Faster Than Our Nano-Headlights AAAS Annual Meeting February 13, 2009 Norris E. Alderson,
Abuse Liability and Drug Scheduling: The Role of the FDA Deborah B
First In Human Pediatric Trials and Safety Assessment for Rare and Orphan Diseases Andrew E. Mulberg, MD, FAAP Division Deputy Director OND/ODE3/DGIEP.
Postmarketing Safety Assessment of Osteonecrosis of the Jaw Pamidronate & Zoledronic Acid Division of Drug Risk Evaluation Office of Drug Safety FDA Carol.
Reproductive Health Drugs, Pregnancy Labeling Subcommittee Meeting March 28-29, 2000 Holli A. Hamilton, M.D., M.P.H. Pregnancy Labeling Team Office of.
Investigational Drugs in the hospital. + What is Investigational Drug? Investigational or experimental drugs are new drugs that have not yet been approved.
General Anesthesia Dr. Israa.
ANESTHETICS Dr.Shadi- Sarahroodi Pharm.D & PhD PUBLISHED BY
Inguinal Hernia of Premature Infants
Humanitarian Use Devices September 23, 2011 Theodore Stevens, MS, RAC Office of Cellular, Tissue and Gene Therapies Center for Biologics Evaluation and.
1 ENTEREG ® (Alvimopan) Special Safety Section Marjorie Dannis, M.D. Division of Gastroenterology Products Office of Drug Evaluation III CDER, FDA The.
Intravenous anesthetics. Toxicity of General Anesthesia.
Joint Dermatologic and Ophthalmic Drugs & Drug Safety and Risk Management Advisory Committee February 26 & 27, 2004 RISK MANAGEMENT OPTIONS FOR PREGNANCY.
Cardiovascular Risk and NSAIDs Arthritis Advisory Committee Meeting November 29, 2006 Sharon Hertz, M.D. Deputy Director Division of Analgesia, Anesthesia,
CNS Depressants Lab # 2.
Embryonic Neural Stem Cells & Potential Anesthetic-Induced Neurotoxicity Cheng Wang, MD., PhD Division of Neurotoxicity National Center of Toxicological.
Food and Drug Administration Center for Drug Evaluation and Research Lessons Learned from Growth Studies with Orally Inhaled and Intranasal Corticosteroids.
History of Pediatric Labeling
1 Operation of the Prescription Drug User Fee Program Janet Woodcock, M.D. Deputy Commissioner for Operations November 14, 2005.
General Regulatory Issues in the Development of Drugs Intended for Treatment of Chronic Illness Sharon Hertz, M.D. Medical Officer Division of Anesthetic,
Introduction to anaesthesia
1 One Year Post Exclusivity Adverse Event Review: Sumatriptan Pediatric Advisory Committee Meeting November 18, 2005 Susan McCune, M.D. Medical Officer.
Stakeholder Meeting on the Implementation of the Medical Device User Fee and Modernization Act of 2002 (MDUFMA) November 17, 2005 Diana Zuckerman, Ph.D.
Initiatives Drive Pediatric Drug Development January 30, 2002.
Drug Regulation, Development, Names, and Information Chapter 3 Copyright (c) 2004 Elsevier Inc. All rights reserved.
Inapsine: Basis for Approval Anesthetics and Life Support Drugs Advisory Committee Meeting November 18, 2002 Arthur Simone, MD, PhD Medical Officer Division.
Pharmacogenetics (PGx) of Irinotecan: Scientific and Clinical Impact of UGT Polymorphism: Background Clinical Pharmacology Subcommittee of ACPS November.
Food and Drug Administration Division of Pulmonary and Allergy Drug Products Summary Comments - Orally Inhaled and Intranasal Budesonide and Fluticasone.
Application of the 1998 Pediatric Rule to Oncology Steven Hirschfeld, MD PhD CDR U.S. Public Health Service Medical Officer Division of Oncology Drug Products.
Overview of Pediatric Drug Development Dianne Murphy, MD Director Office of Counterterrorism and Pediatric Drug Development Center for Drug Evaluation.
1 One Year Post Exclusivity Adverse Event Review: Glimepiride Pediatric Advisory Committee Meeting November 16, 2006 Hari Cheryl Sachs, MD, FAAP Medical.
Pediatric Advisory Committee: Overview of Role and Evolution of Process Dr. Dianne Murphy Director, Office of Pediatric Therapeutics, OC, FDA November.
Copyright © 2016, 2013, 2010 by Saunders, an imprint of Elsevier Inc. All rights reserved. Chapter 9 to 11 Drug Therapy Across the Lifespan.
FDA’s Role in the Risk Management of Opiate Analgesics Steven Galson, M.D., M.P.H. Deputy Center Director, Center for Drug Evaluation and Research Food.
Anesthesia for Non-Obstetric Surgery Most common reasons for surgery: – Appendicitis – Cholecystitis – Trauma – Ovarian torsion.
Anesthesia Part 3 By Alaina Darby.
GENERAL ANAESTHETIC AGENTS By Afsar fathima.
Clinical Trials — A Closer Look
General Anesthesia.
General Anesthesia.
School of Pharmacy, University of Nizwa
Analgesia.
Introduction to Clinical Pharmacology Chapter 17 Anesthetic Drugs
CNS Depressants Lab # 2.
Statement on Concerta and Methylphenidate for the June 30, 2005 Pediatric Advisory Committee The FDA has identified two possible safety concerns with.
Introductory Clinical Pharmacology Chapter 21 Anesthetic Drugs
Pediatric Therapeutics Still working to get it right for kids
NON VOLATILE ANESTHETIC AGENTS( Intravenous Anesthetics)
Regulatory Perspective of the Use of EHRs in RCTs
Design Issues in Human studies of Psychopharmacology placebo controls double blind studies.
Presentation transcript:

Overview and Regulatory Issues Regarding Anesthetic Agents for Pediatric Patients Anesthetics and Life Support Drugs Advisory Committee Meeting March 29, 2007 Arthur Simone, MD, PhD Division of Anesthesia, Analgesia and Rheumatology Products Anesthetics and Life Support Drugs Advisory Committee Meeting March 29, 2007 Arthur Simone, MD, PhD Division of Anesthesia, Analgesia and Rheumatology Products Center for Drug Evaluation and Research

Anesthetics and Life Support Drugs Advisory Committee March 29, The Issue Synaptogenesis (brain growth spurt) Highly regulated period of brain development A process that appears conserved among species –Rodents: 2 days before to 2 weeks after birth –Humans: 3 rd trimester to ~ 3 years of age Second spurt observed in humans during late adolescence Adversely affected by environmental conditions Synaptogenesis (brain growth spurt) Highly regulated period of brain development A process that appears conserved among species –Rodents: 2 days before to 2 weeks after birth –Humans: 3 rd trimester to ~ 3 years of age Second spurt observed in humans during late adolescence Adversely affected by environmental conditions

Anesthetics and Life Support Drugs Advisory Committee March 29, The Issue Glutamate and γ -amino-butyric acid (GABA) –Non-synaptic trophic factors –Promote neuronal arbor elaboration GABA-receptor stimulation and N-methyl D- aspartate (NMDA) receptor blockade –Deleterious effects on neural development –Apoptosis - programmed cell death Single cell Shrunken, preserved plasma membrane Non-inflammatory Glutamate and γ -amino-butyric acid (GABA) –Non-synaptic trophic factors –Promote neuronal arbor elaboration GABA-receptor stimulation and N-methyl D- aspartate (NMDA) receptor blockade –Deleterious effects on neural development –Apoptosis - programmed cell death Single cell Shrunken, preserved plasma membrane Non-inflammatory

Anesthetics and Life Support Drugs Advisory Committee March 29, Receptor Activity of Commonly Used Anesthetic Agents

Anesthetics and Life Support Drugs Advisory Committee March 29, Anesthesia and the Vulnerable Patient Exposures –Maternal surgery –In-utero surgery –Labor and delivery/Cesarian section –Surgical procedures from birth to age 3 years Alternative Therapies –Neuraxial/regional/local anesthesia –Opioid anesthesia –No anesthesia –Delay surgery Exposures –Maternal surgery –In-utero surgery –Labor and delivery/Cesarian section –Surgical procedures from birth to age 3 years Alternative Therapies –Neuraxial/regional/local anesthesia –Opioid anesthesia –No anesthesia –Delay surgery

Anesthetics and Life Support Drugs Advisory Committee March 29, Commonly Used Anesthetic Agents

Anesthetics and Life Support Drugs Advisory Committee March 29, Commonly Used Anesthetic Agents With Pediatric Specific Labeling

Anesthetics and Life Support Drugs Advisory Committee March 29, Commonly Used Anesthetic Agents With Any Pediatric Specific Labeling for Ages ≤ 3 years

Anesthetics and Life Support Drugs Advisory Committee March 29, Classification of Drug Products for Use During Pregnancy 21 CFR § A - human studies show no risk B - animal studies show risk but human studies do not C - animal studies show risk but no human studies conducted, or no studies at all D - evidence of human fetal risk X - studies have demonstrated animal or human fetal abnormalities and risk outweighs any possible benefit. 21 CFR § A - human studies show no risk B - animal studies show risk but human studies do not C - animal studies show risk but no human studies conducted, or no studies at all D - evidence of human fetal risk X - studies have demonstrated animal or human fetal abnormalities and risk outweighs any possible benefit.

Anesthetics and Life Support Drugs Advisory Committee March 29, Commonly Used Anesthetic Agents – With a Pregnancy Classification of A or B Methohexital Propofol Enflurane Desflurane Sevoflurane Lidocaine Lidocaine-Prilocaine Ropivacaine cis-atracurium Methohexital Propofol Enflurane Desflurane Sevoflurane Lidocaine Lidocaine-Prilocaine Ropivacaine cis-atracurium

Anesthetics and Life Support Drugs Advisory Committee March 29, Milestones for Drug Regulation Thiopental (clinical use; never approved for parenteral) The Federal Food, Drug, and Cosmetic (FDC) Act Meperidine Halothane Methohexital Kefauver-Harris Drug Amendments NAS and NRC to assess efficacy of 4,000 drugs approved FDA forms Drug Efficacy Study Implementation (DESI) to implement recommendations of the NAS Fentanyl Ketamine National Center for Toxicological Research established – Isoflurane, Etomidate, Midazolam, Propofol, Desflurane Regulations promulgated stating that there must be a pediatric use section in the label Sevoflurane Food and Drug Modernization Act Pediatric Rule The Best Pharmaceuticals for Children Act Pediatric Research Equity Act Thiopental (clinical use; never approved for parenteral) The Federal Food, Drug, and Cosmetic (FDC) Act Meperidine Halothane Methohexital Kefauver-Harris Drug Amendments NAS and NRC to assess efficacy of 4,000 drugs approved FDA forms Drug Efficacy Study Implementation (DESI) to implement recommendations of the NAS Fentanyl Ketamine National Center for Toxicological Research established – Isoflurane, Etomidate, Midazolam, Propofol, Desflurane Regulations promulgated stating that there must be a pediatric use section in the label Sevoflurane Food and Drug Modernization Act Pediatric Rule The Best Pharmaceuticals for Children Act Pediatric Research Equity Act

Anesthetics and Life Support Drugs Advisory Committee March 29, Securing Pediatric Indications Drug is initially approved for adult use. Preclinical evaluation in juvenile animals is not always required. –Guidance for Industry: “Nonclinical Safety Evaluation of Pediatric Drug Products” (Feb., 2006) Pediatric clinical trials are primarily designed for determining efficacious dosing requirements. Assessment of safety – findings from adult trials and new findings from pediatric clinical trials Drug is initially approved for adult use. Preclinical evaluation in juvenile animals is not always required. –Guidance for Industry: “Nonclinical Safety Evaluation of Pediatric Drug Products” (Feb., 2006) Pediatric clinical trials are primarily designed for determining efficacious dosing requirements. Assessment of safety – findings from adult trials and new findings from pediatric clinical trials

Anesthetics and Life Support Drugs Advisory Committee March 29, AlternativesAlternatives Local anesthetics Narcotic-only anesthesia No anesthesia/sedation Delay procedure Local anesthetics Narcotic-only anesthesia No anesthesia/sedation Delay procedure

Anesthetics and Life Support Drugs Advisory Committee March 29, Local Anesthetics Topical, regional, and neuraxial anesthesia may be suitable for some procedures. Toxicities in pediatric patients have not been fully elucidated. Sedation is generally utilized for anxiolysis and amnesia. Topical, regional, and neuraxial anesthesia may be suitable for some procedures. Toxicities in pediatric patients have not been fully elucidated. Sedation is generally utilized for anxiolysis and amnesia.

Anesthetics and Life Support Drugs Advisory Committee March 29, OpioidsOpioids May be suitable for some procedures. Toxicities for pediatric patients have not been fully elucidated. Sedation is generally utilized for anxiolysis and amnesia. May be suitable for some procedures. Toxicities for pediatric patients have not been fully elucidated. Sedation is generally utilized for anxiolysis and amnesia.

Anesthetics and Life Support Drugs Advisory Committee March 29, No Anesthesia May work for some procedures Research demonstrates –Morphological changes in rodent brains –Premature infants show metabolic stress responses post operatively that can be blocked by intravenous opioids. –The increasing crying and behavioral changes occur for days after circumcision can be blocked with the use of regional anesthesia. –4- to 6-month old infants circumcised without analgesia had higher pain scores than those circumcised with analgesia as measured by observable indicators such as facial expression, length of crying, and body movement –by 6 months of age, children demonstrate anticipatory fear when taken to places where they experienced pain in the past May work for some procedures Research demonstrates –Morphological changes in rodent brains –Premature infants show metabolic stress responses post operatively that can be blocked by intravenous opioids. –The increasing crying and behavioral changes occur for days after circumcision can be blocked with the use of regional anesthesia. –4- to 6-month old infants circumcised without analgesia had higher pain scores than those circumcised with analgesia as measured by observable indicators such as facial expression, length of crying, and body movement –by 6 months of age, children demonstrate anticipatory fear when taken to places where they experienced pain in the past

Anesthetics and Life Support Drugs Advisory Committee March 29, AERS Database Post-approval safety data collection Limitations –Voluntary –Submitter status –Data captured Timing of adverse event Nature of events Missing data –Numerator/Denominator Post-approval safety data collection Limitations –Voluntary –Submitter status –Data captured Timing of adverse event Nature of events Missing data –Numerator/Denominator

Anesthetics and Life Support Drugs Advisory Committee March 29, Ketamine and AERS Database Office of Surveillance and Epidemiology Between approval and pediatric (≤ 16 years old) reports SOCs selected: –Musculoskeletal –Nervous –Psychiatric Office of Surveillance and Epidemiology Between approval and pediatric (≤ 16 years old) reports SOCs selected: –Musculoskeletal –Nervous –Psychiatric

Anesthetics and Life Support Drugs Advisory Committee March 29, Ketamine and AERS Database 58 reports found – (n=9) – (n=5) – (n=22) – (n=22) There were 4 fatalities. 25 reports involved at least one other NMDA/GABA acting anesthetic 58 reports found – (n=9) – (n=5) – (n=22) – (n=22) There were 4 fatalities. 25 reports involved at least one other NMDA/GABA acting anesthetic

Anesthetics and Life Support Drugs Advisory Committee March 29, Ketamine and AERS Database convulsions (n=9) hallucination (n=6) drug ineffective (n=8) medication error (n=6) sedation (n=8) abnormal dreams (n=5) pyrexia (n=7) anesthetic complication (n=5) bradycardia (n=6) coma (n=4) convulsions (n=9) hallucination (n=6) drug ineffective (n=8) medication error (n=6) sedation (n=8) abnormal dreams (n=5) pyrexia (n=7) anesthetic complication (n=5) bradycardia (n=6) coma (n=4)

Anesthetics and Life Support Drugs Advisory Committee March 29, Where do we stand? A safety signal has been identified in animals for many drugs used to provide sedation and anesthesia. The relevance of the animal findings to pediatric patients is unknown. The need to provide sedation and anesthesia cannot be avoided in many situations. There is no available alternative therapy proven to be safer. A safety signal has been identified in animals for many drugs used to provide sedation and anesthesia. The relevance of the animal findings to pediatric patients is unknown. The need to provide sedation and anesthesia cannot be avoided in many situations. There is no available alternative therapy proven to be safer.